romiplostim N01 + dexamethasone

Romiplostim N01 + dexamethasone is a **combination therapy under clinical investigation** for the first-line treatment of adult patients with newly diagnosed **primary immune thrombocytopenia (ITP)**. Romiplostim N01 is a biosimilar or specific formulation of **romiplostim**, a thrombopoietin receptor agonist that stimulates the production of platelets by activating the thrombopoietin receptor (c-Mpl) on megakaryocyte precursors. It is combined with **dexamethasone**, a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, which broadly suppresses immune-mediated platelet destruction. The combination aims to improve initial response and long-term platelet count stability over either agent used alone. Romiplostim N01 is administered subcutaneously, while dexamethasone can be given orally or intravenously. The regimen has entered **Phase 2 and Phase 3 clinical trials** assessing efficacy, safety, and quality-of-life outcomes for patients with ITP[1][3][4][6][7].